Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
Total Valuation
ARS Pharmaceuticals has a market cap or net worth of $801.33M. The enterprise value is $831.65M.
Market Cap$801.33M
Enterprise Value$831.65M
Share Statistics
ARS Pharmaceuticals has 99,297,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99,297,310
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ARS Pharmaceuticals’s return on equity (ROE) is -1.50 and return on invested capital (ROIC) is -62.04%.
Return on Equity (ROE)-1.50
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-62.04%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee543.73K
Profits Per Employee-1.11M
Employee Count155
Asset Turnover0.26
Inventory Turnover2.44
Valuation Ratios
The current PE Ratio of ARS Pharmaceuticals is ―. ARS Pharmaceuticals’s PEG ratio is 0.00303.
PE Ratio―
PS Ratio13.63
PB Ratio10.05
Price to Fair Value10.05
Price to FCF-6.71
Price to Operating Cash Flow-4.51
PEG Ratio0.00303
Income Statement
In the last 12 months, ARS Pharmaceuticals had revenue of 84.28M and earned -171.30M in profits. Earnings per share was -1.74.
Revenue84.28M
Gross Profit63.85M
Operating Income-179.45M
Pretax Income-171.38M
Net Income-171.30M
EBITDA-178.08M
Earnings Per Share (EPS)-1.74
Cash Flow
In the last 12 months, operating cash flow was -170.87M and capital expenditures -339.00K, giving a free cash flow of -171.21M billion.
Operating Cash Flow-170.87M
Free Cash Flow-171.21M
Free Cash Flow per Share-1.72
Dividends & Yields
ARS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.36
52-Week Price Change-35.59%
50-Day Moving Average9.31
200-Day Moving Average11.60
Relative Strength Index (RSI)42.01
Average Volume (3m)1.32M
Important Dates
ARS Pharmaceuticals upcoming earnings date is May 19, 2026, After Close (Confirmed).
Last Earnings DateMar 9, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
ARS Pharmaceuticals as a current ratio of 7.28, with Debt / Equity ratio of 84.86%
Current Ratio7.28
Quick Ratio7.06
Debt to Market Cap0.08
Net Debt to EBITDA-0.31
Interest Coverage Ratio-69.05
Taxes
In the past 12 months, ARS Pharmaceuticals has paid -80.00K in taxes.
Income Tax-80.00K
Effective Tax Rate<0.01
Enterprise Valuation
ARS Pharmaceuticals EV to EBITDA ratio is -6.76, with an EV/FCF ratio of -7.03.
EV to Sales14.29
EV to EBITDA-6.76
EV to Free Cash Flow-7.03
EV to Operating Cash Flow-7.05
Balance Sheet
ARS Pharmaceuticals has $244.99M in cash and marketable securities with $96.96M in debt, giving a net cash position of $148.02M billion.
Cash & Marketable Securities$244.99M
Total Debt$96.96M
Net Cash$148.02M
Net Cash Per Share$1.49
Tangible Book Value Per Share$1.01
Margins
Gross margin is 75.77%, with operating margin of -212.92%, and net profit margin of -203.25%.
Gross Margin75.77%
Operating Margin-212.92%
Pretax Margin-203.35%
Net Profit Margin-203.25%
EBITDA Margin-211.30%
EBIT Margin-212.92%
Analyst Forecast
The average price target for ARS Pharmaceuticals is $19.28, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$19.28
Price Target Upside138.91% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast5459.66%
EPS Growth Forecast-59.70%